199 related articles for article (PubMed ID: 22035432)
1. TNF inhibitors for rheumatoid arthritis - a year in review.
Simsek I
Bull NYU Hosp Jt Dis; 2011; 69(3):220-4. PubMed ID: 22035432
[TBL] [Abstract][Full Text] [Related]
2. TNF inhibitors - new and old agents for rheumatoid arthritis.
Simsek I
Bull NYU Hosp Jt Dis; 2010; 68(3):204-10. PubMed ID: 20969553
[TBL] [Abstract][Full Text] [Related]
3. Predictors of response to TNF inhibitors in rheumatoid arthritis - do we have new tools for personalized medicine?
Simsek I
Bull NYU Hosp Jt Dis; 2012; 70(3):187-90. PubMed ID: 23259626
[TBL] [Abstract][Full Text] [Related]
4. TNF-alpha antagonism and cancer risk in rheumatoid arthritis: is continued vigilance warranted?
Park HJ; Ranganathan P
Discov Med; 2012 Mar; 13(70):229-34. PubMed ID: 22463799
[TBL] [Abstract][Full Text] [Related]
5. Emerging therapeutics for rheumatoid arthritis.
Bingham CO
Bull NYU Hosp Jt Dis; 2008; 66(3):210-5. PubMed ID: 18937634
[TBL] [Abstract][Full Text] [Related]
6. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Watson KD; Silman AJ; Symmons DP;
Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
[TBL] [Abstract][Full Text] [Related]
7. An update on pharmacogenomics in rheumatoid arthritis with a focus on TNF-blocking agents.
Ranganathan P
Curr Opin Mol Ther; 2008 Dec; 10(6):562-7. PubMed ID: 19051134
[TBL] [Abstract][Full Text] [Related]
8. Intensive treatment and treatment holiday of TNF-inhibitors in rheumatoid arthritis.
Tanaka Y
Curr Opin Rheumatol; 2012 May; 24(3):319-26. PubMed ID: 22388646
[TBL] [Abstract][Full Text] [Related]
9. Tumor necrosis factor inactivation in the management of rheumatoid arthritis.
Baumgartner SW
South Med J; 2000 Aug; 93(8):753-9. PubMed ID: 10963503
[TBL] [Abstract][Full Text] [Related]
10. Utilization trends of tumor necrosis factor inhibitors among patients with rheumatoid arthritis in a United States observational cohort study.
Lee SJ; Chang H; Yazici Y; Greenberg JD; Kremer JM; Kavanaugh A
J Rheumatol; 2009 Aug; 36(8):1611-7. PubMed ID: 19369454
[TBL] [Abstract][Full Text] [Related]
11. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
Braun-Moscovici Y; Markovits D; Rozin A; Toledano K; Nahir AM; Balbir-Gurman A
Isr Med Assoc J; 2008 Apr; 10(4):277-81. PubMed ID: 18548981
[TBL] [Abstract][Full Text] [Related]
12. Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors.
Kapetanovic MC; Roseman C; Jönsson G; Truedsson L; Saxne T; Geborek P
Arthritis Rheum; 2011 Dec; 63(12):3723-32. PubMed ID: 21834061
[TBL] [Abstract][Full Text] [Related]
13. Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety.
Komano Y; Tanaka M; Nanki T; Koike R; Sakai R; Kameda H; Nakajima A; Saito K; Takeno M; Atsumi T; Tohma S; Ito S; Tamura N; Fujii T; Sawada T; Ida H; Hashiramoto A; Koike T; Ishigatsubo Y; Eguchi K; Tanaka Y; Takeuchi T; Miyasaka N; Harigai M;
J Rheumatol; 2011 Jul; 38(7):1258-64. PubMed ID: 21498482
[TBL] [Abstract][Full Text] [Related]
14. Immunological therapies for rheumatoid arthritis.
Edwards CJ
Br Med Bull; 2005; 73-74():71-82. PubMed ID: 16174791
[TBL] [Abstract][Full Text] [Related]
15. [TNF-alpha antibody in rheumatoid arthritis. Efficacy-risk relationship is positively evaluated].
MMW Fortschr Med; 2002 May; 144(20):65. PubMed ID: 12119893
[No Abstract] [Full Text] [Related]
16. Tolerance and effectiveness of anti-tumor necrosis factor alpha therapies in elderly patients with rheumatoid arthritis: a population-based cohort study.
Genevay S; Finckh A; Ciurea A; Chamot AM; Kyburz D; Gabay C;
Arthritis Rheum; 2007 May; 57(4):679-85. PubMed ID: 17471545
[TBL] [Abstract][Full Text] [Related]
17. Emerging biologic drugs for the treatment of rheumatoid arthritis.
Puppo F; Murdaca G; Ghio M; Indiveri F
Autoimmun Rev; 2005 Nov; 4(8):537-41. PubMed ID: 16214092
[TBL] [Abstract][Full Text] [Related]
18. TNF alpha as a therapeutic target in rheumatoid arthritis.
Feldmann M; Brennan FM; Elliott M; Katsikis P; Maini RN
Circ Shock; 1994 Aug; 43(4):179-84. PubMed ID: 7895323
[TBL] [Abstract][Full Text] [Related]
19. Comparative overview of safety of the biologics in rheumatoid arthritis.
Khraishi M
J Rheumatol Suppl; 2009 Jun; 82():25-32. PubMed ID: 19509327
[TBL] [Abstract][Full Text] [Related]
20. Insulin resistance in rheumatoid arthritis: the impact of the anti-TNF-alpha therapy.
Gonzalez-Gay MA; Gonzalez-Juanatey C; Vazquez-Rodriguez TR; Miranda-Filloy JA; Llorca J
Ann N Y Acad Sci; 2010 Apr; 1193():153-9. PubMed ID: 20398022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
